Finally, Blanco and colleagues [76] recently screened a large series of 516 BRCA1/BRCA2-negative patients from breast and/or ovarian cancer families for RAD51C mutations and identified 3 germline pathogenic mutations. This evidence concerns the gene RAD51C and ovarian carcinoma.